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Abstract: One out of every 2 women within postmenopause are at risk of fracture due to 
  osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this 
disease and prevent fracture. A new class of anabolic agents has emerged within the last decade 
that brought with it a new concept in osteoporosis therapy: building new stronger bone rather 
than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize 
these new agents, and which patients benefit most. This article will review the effectiveness, 
risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.
Keywords: osteoporosis, menopause, teriparatide
Background
With the aging population and the resultant expected rise in fracture prevalence in the 
near future, there is growing interest in expanding therapies for osteoporosis (OP). 
Although OP occurs in men and younger women, postmenopausal women remain 
most effected, with a lifetime risk of fracture of 50%.1 The past 2 decades have seen 
incredible innovation in the bone field. The 1990s brought the bisphosphonates (BPS), 
a class of bone specific agents with versatile dosing options, impressive efficacy, and 
relative safety. Other advances in OP treatment came when estrogen was proven to 
prevent hip fracture in the Women’s Health Initiative, but enthusiasm was limited by 
the discovery of potential adverse effects likely associated with timing of initiation that 
limits its more widespread use. The selective estrogen receptor modulator class was 
discovered and expanded, but has limitations due to side effects, gender restrictions, 
and the lack of hip fracture reduction. Although multiple drugs are available to treat 
OP, they had all previously belonged to the anti-catabolic group, acting by inhibiting 
bone turnover. An entirely new class of therapeutic agents for OP was announced in 
2002 with the Food and Drug Administration (FDA) approval of teriparatide, the first 
medication available with an anabolic mechanism.
Teriparatide (Forteo® [US], Forsteo® [Europe]; Eli Lilly and Co.) is a recombinant 
formulation of endogenous parathyroid hormone (PTH), containing a 34-amino-acid 
sequence which is identical to the N-terminal portion of the human hormone 
[rhPTH(1-34)]. Though human recombinant parathyroid hormone (rhPTH [1-84]) 
(Preotact®; Nycomed) and synthetic human parathyroid hormone (hPTH [1-34]) are 
other anabolic agents that have also been used in clinical trials, they are not approved 
for use in the United States (US) at this time, and so we will focus on teriparatide 
in our review.International Journal of Women’s Health 2010:2 38
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Efficacy
This fragment known as teriparatide (1-34), retains the 
bone-forming effects of the full-length human PTH, stimu-
lating osteoblast function, increasing gastrointestinal cal-
cium absorption, and increasing renal tubular reabsorption 
of calcium. When considering the significant bone loss that 
can occur with the disease hyperparathyroidism, the treat-
ment of OP with the use of a PTH analogue may initially 
seem counterintuitive. Indeed, continuous high levels of 
PTH do mobilize calcium from the bone and accelerates 
bone loss; however, pulsatile exposure to lower doses, as 
occurs with once daily dosing with teriparatide, actually 
results in increased bone mineral density (BMD) and bone 
mass, with the improvement seen in both cancellous and 
cortical bone architecture.2–5 Although generalized bone 
remodeling is stimulated, there is a net favoring of bone 
formation, possibly due to the inhibition of osteoblast 
apoptosis or the transformation of bone lining cells back 
to functional osteoblasts.6,7 This is reflected in bone marker 
behavior with teriparatide therapy. Bone formation mark-
ers rise more rapidly and peak within the first 3 months of 
therapy with teriparatide, as compared to the bone resorption 
markers, which peak later at 6 months. This delay between 
bone formation overriding bone resorption is referred to 
as the “anabolic window.” This is an important concept to 
understand as it has significant potential implications on 
optimal dosing duration and sequencing. This initial favor-
ing of bone formation results in new bone that has increased 
strength and microarchitecture. Skeletal areas comprised of 
cancellous bone (lumbar spine) see more rapid and quantita-
tive increases overall from teriparatide therapy than sites of 
cortical bone (femoral neck and radius).8
Teriparatide is FDA approved for the treatment of OP in 
postmenopausal women at highest risk for fracture, primary 
or hypogonadal OP in men at high fracture risk, and glu-
cocorticoid-induced osteoporosis (GIOP) in both men and 
women. As with most studies of therapies for OP, proving 
true fracture reduction, which in the end is the most important 
outcome, is inherently difficult. Such studies require large 
sample sizes over many years, which are difficult to complete. 
Thus, surrogate markers such as BMD and bone formation 
and turnover markers are often used to assess pharmacologic 
efficacy.
Teriparatide at 20 µg/day has been proven to decrease 
spine and nonvertebral fractures except hip fractures in post-
menopausal women with prior vertebral fractures, reducing 
the incidence of new vertebral fractures as identified by visual 
semiquantitative readings by 65%, and nonvertebral fractures 
by 53% compared to placebo, after 12 months of therapy. 
Dosing with 40 µg/day was not superior and thus this dose 
was not approved.9 When quantitative morphometry was 
also used to diagnose the fractures, an even higher vertebral 
fracture reduction of 84% was seen.10
Multiple scenarios are raised when considering therapy 
with teriparatide: use following other prior therapies, use in 
those who are on concomitant therapy with other agents, and, 
least commonly, use in the treatment-naïve group. Reasons to 
consider switching therapy to teriparatide from other thera-
pies may be new fracture or loss of BMD on current therapy 
and/or drug intolerance. Of course, a true failure of therapy 
must first include a re-evaluation of potentially new second-
ary causes and compliance with not only the bone agent but 
also with calcium and vitamin D supplementation.
Sequential therapy
Sequential therapy is often considered in patients who are 
already on an anti-resorptive medication but have subse-
quently fractured or continued to lose bone mass leading to 
the decision to switch to an anabolic agent. Another scenario 
are those who have an intolerance or a contraindication to 
one of the other bone agents, although less common now 
with the use of intravenous (IV) zoledronic acid (Reclast®; 
Novartis) and IV ibandronate (Boniva®; Genentech), which 
can circumvent gastrointestinal contraindications to BPS, as 
well as compliance issues. Some even consider switching 
to an anabolic agent in severe OP if there remains increased 
bone turnover by marker assessment, despite treatment with 
an IV BPS that does not rely on oral absorption.
Teriparatide appears to retain its anabolic effect in 
postmenopausal women with OP previously treated with 
long term BPS, although it is believed that the benefits is 
probably less than that seen in previously untreated patients, 
with less relative increases in BMD and markers of bone 
formation.11 Ettinger et al studied postmenopausal women 
who had previously received alendronate or raloxifene fol-
lowed by teriparatide given at 20 µg/day. Increases in lumbar 
spine were more robust after 18 months in those previously 
treated with raloxifene than those treated with alendronate 
(10.2% vs 4.1%, P  0.05) and increases in mean total hip 
BMD were seen only in those previously treated with raloxi-
fene.12 A study by Eastell compared teriparatide therapy in 
postmenopausal women with OP who were previously BPS 
naïve, to those who had previously received a BPS, who were 
further defined as being adequate responders vs inadequate 
responders to BPS. Inadequate responders were defined as 
having 1 new clinical fragility fracture after 12 months International Journal of Women’s Health 2010:2 39
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of therapy, a T-score  –3.0, or a BMD decrease 3.5% at 
either the spine, total hip, or femoral neck after 24 months 
of therapy. All groups demonstrated significant increases 
in lumbar spine BMD; however, the greatest response was 
seen in the treatment naïve group at 13.5%, with 10.8% in 
the adequate responders to BPS group and 9.7% seen in the 
inadequate responders group.13
This blunting of response to PTH therapy following BPS 
treatment may have to do with the avidity of BPS binding 
to hydroxyapatite in osteoclasts, which varies by BPS type. 
This was indeed shown by Miller et al where postmeno-
pausal women with OP were treated with PTH following 
either alendronate, which has a higher binding affinity, vs 
risedronate therapy. Significant blunting was seen in the 
  alendronate-treated group, with only 13.7% increase in quan-
titative computerized tomography (QCT) of trabecular bone 
at the spine vs 24% seen with those who received risedronate, 
which has known lower binding affinity (P = 0.023).14
Treatment-naïve patients
When comparing teriparatide vs alendronate in postmeno-
pausal osteoporotic women, teriparatide increased BMD at 
the lumbar spine, femoral neck, and total body to a greater 
degree than alendronate, but BMD at the one third distal 
radius decreased. Nonvertebral fracture frequency was sig-
nificantly lower in the teriparatide treated group (4.1%) than 
in the alendronate group (13.7%, P = 0.042).15 Unfortunately, 
not many direct comparisons of fracture reduction can be 
made compared to other antiresorptive agents due to a lack 
of head-to-head studies looking at fracture outcomes. Saag 
et al evaluated teriparatide vs alendronate therapy in women 
and men with GIOP and showed not only greater increases in 
lumbar spine BMD, but favored teriparatide as being more 
effective than BPS in preventing vertebral fractures (1.7% vs 
7.7%, P = 0.007). However, there was no difference in non-
vertebral fracture rates.16
Combination therapy
Several studies have evaluated outcomes related to combining 
teriparatide and other OP therapies in postmenopausal 
women. Black and colleagues assessed the differences in 
BMD with rhPTH (1-84) alone, in combination with alen-
dronate, vs alendronate alone in postmenopausal women with 
low BMD at the hip or spine. This study showed that adding 
a BPS to an anabolic therapy blunted the response seen in 
treatment-naïve patients who were given anabolic therapy 
alone. Although BMD of the spine (measured by DXA 
and QCT) increased significantly in all treatment groups 
after 12 months of treatment, the increase in the rhPTH 
(1-84) only group was approximately twice that found when 
alendronate was added to rhPTH (1-84) (25.5% vs 12.9%; 
P = 0.01). Similarly, bone formation markers increased only 
in the rhPTH (1-84) group vs. decreased in the combination 
group.17 Similar to findings in postmenopausal women with 
OP, concomitant therapy with teriparatide and alendronate in 
men blunted the increase in lumbar spine and femoral neck 
BMD seen in teriparatide monotherapy.18 The study results 
of Cosman et al challenge the above findings of blunting 
with concomitant BPS and anabolic therapy. In comparing 
those who are treated with teriparatide as add on therapy to 
baseline alendronate or raloxifene use vs. teriparatide alone, 
this study showed significant decreases in bone turnover with 
combination therapy, and is still underway via an extension 
to follow out these changes.19
With the advent of FDA approval of less frequent IV 
BPS options, studies have begun to assess if this anabolic 
blunting effect differs with variations in BPS dosing intervals. 
Gasser et al found that when a single high dose of iv zole-
dronic acid was given followed by daily injections of PTH, 
there was no blunting of the response to PTH as measured by 
peripheral QCT. In a separate treatment arm, the same BPS 
was administered three times per week, and this regimen did 
cause a blunting of the relative PTH response.20 This sug-
gests that intermittent high doses of zoledronic acid given 
concomitantly with anabolic therapies may not have the same 
blunting effect as does more regular BPS dosing.
Estrogen and raloxifene do not appear to blunt the ana-
bolic effect of PTH like BPS. In fact, some studies show that 
combination therapy with these agents has a small additive 
effect on BMD, with estrogen-hPTH (1-34) treatment result-
ing in increased vertebral BMD in one study and raloxifene-
hPTH (1-34) resulting in increased vertebral and total hip 
BMD in another.21,22
In summary, the true impact of combination therapy on 
fracture rates is unknown. Most combination trials to date have 
been small trials of short duration with various combinations. 
Even less is known about the effects of combination therapy 
in those with GIOP. There are also concerns about potential 
over-suppression of bone. This is an area of ongoing research. 
The official stand of the National Osteoporosis Foundation is 
that the added cost and potential side effects of combination 
therapy should be weighed against potential gains.1
Indications and use
Teriparatide is indicated in the treatment of OP in postmeno-
pausal women, primary or hypogonadal OP in men, and International Journal of Women’s Health 2010:2 40
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GIOP in both men and women. Specifically, patients should 
be at high risk of fracture, such as those with a prior fragil-
ity fracture, multiple risk factors for fracture, and those who 
have failed or are intolerant to other meds. Of course, it is 
important to remember that anyone who fractures while on an 
antiresorptive medication has not necessarily had a treatment 
failure since no therapeutic agent has been shown to totally 
eliminate the risk of fractures. Detailed history and second-
ary evaluation is always prudent before changing therapy. 
Teriparatide can also be considered as first line treatment in 
those who have a T-score -3 if they have other risk fac-
tors for fracture, assuming reversible secondary causes have 
been investigated.23 As with other OP therapies, excluding 
metabolic bone diseases other than primary OP is critical 
prior to initiating therapy, as this medication is not indicated 
for metabolic bone disease other than OP at this time. The 
lack of studies showing hip fracture reduction should not 
limit the use of teriparatide, given that very few bone agents 
in clinical use today have been proven to help reduce hip 
fracture based on prospective randomized studies (with the 
exception of estrogen therapy: Fosamax®; Merck and Co., 
Inc., and zoledronic acid).
Teriparatide is given as a 20 µg subcutaneous injection 
once daily into the thigh or abdominal wall. Currently, it is 
not approved for use longer than 2 years in the US (18 months 
in the EU). The reason for this time limitation is due to the 
association of teriparatide with an increased risk of osteo-
sarcoma in rat studies. This risk seems to be related to both 
dose and duration of the medication (see Precautions and 
contraindications for wider discussion). Patients should be 
easily able to sit down during initial administration in the 
event of orthostasis. Transient orthostatic hypotension usu-
ally occurs within 4 hours of dosing and it is usually limited 
to the first several doses. Recommending dosing at bedtime 
may help to minimize this occurrence. The injection pen was 
recently redesigned to a simpler design; however, patients 
should still receive formal training in the proper use of the 
device prior to initiation. It also requires refrigeration, which 
can raise storage issues during travel.
Similar to endogenous PTH, teriparatide can cause hyper-
calcemia; however, this rise is transient due to the pulsatile 
nature of dosing and short half-life of 1 hour. Rapid peak 
serum concentration is seen within 30 minutes of admin-
istration with good bioavailability (95%) and subsequent 
clearance of serum levels within 3 hours. Although unstudied 
specific to the drug, clearance is presumed to be the same 
as that of endogenous PTH, with metabolism mainly in the 
liver with excretion by the kidneys.8,24
Cost effectiveness
Teriparatide is quite expensive compared to most alternative 
bone agents currently available. At approximately 
US$800/month, it can be anywhere from 10 to 30 times 
more costly than oral BPS therapy, or even greater with the 
generic formulation of alendronate being available.
As with any medication for OP, which has a vari-
able population prevalence with additional confounders 
like vitamin D and calcium sufficiency, determining cost 
effectiveness amongst therapies is complex. Results of cost 
effectiveness evaluations with teriparatide are likewise based 
on a number of assumptions, data limitations, and can be 
difficult to extrapolate to populations beyond those studied. 
Such is the case for men and those with GIOP, as none yet 
have evaluated these groups for cost effectiveness.
Cost considerations and questionable effect on hip 
fracture reduction prohibit using teriparatide as first line 
therapy for the general population. However, utilizing this 
medication in women aged 65 with BMD  -3 and recent 
fragility fractures has been shown to be an effective economic 
option when considering quality adjusted life-years vs no 
therapy.23
Precautions and contraindications
Data are limited for the use of this medication in those with 
cardiovascular, hepatic, or liver disease; thus, caution should 
be used in those with severe renal and hepatic impairment. 
Teriparatide should also be used with caution in patients with 
active or recent urolithiasis. No dosage adjustment is required 
with renal insufficiency, though bioavailability and half-life 
may increase when Clcr  30 mL/minute. One must ensure 
that there is not a resultant pre-existing hyperparathyroid state 
due to severe renal insufficiency, though, before proceeding 
with teriparatide use. Teriparatide is contraindicated in those 
with hypercalcemia and hyperparathyroidism.
As stated above, the FDA black box warning limiting 
therapy duration to 2 years relates to the association of 
teriparatide with an increased risk of osteosarcoma in rat 
studies. This risk was related to both dose and duration of 
the medication. However, one limitation of these rat studies 
is that very high doses were used in the rat’s short life cycle. 
In the original study, the rats were treated for nearly their 
entire life span (70% to 80% of their lifetime) and during 
the rapid phase of longitudinal skeletal growth (starting at 
approximately 2 months of age). The rats were also treated 
with relative supratherapeutic doses for their size. Also, 
interestingly, the studied Fischer-344 rats have a 1000-fold International Journal of Women’s Health 2010:2 41
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higher baseline risk of osteosarcoma as compared to humans 
prior to any treatment.25
In contrast, the intended clinical use of teriparatide in 
humans only encompasses 2%–3% of the human life span, 
and is given to adults, in the setting of a mature skeleton with 
already closed epiphyseal plates. Subsequently, a repeat study 
was done by the same researchers looking at osteosarcoma 
risks as it relates to age at treatment as well as dose range 
(varying between 3 and 60 times higher than what is approved 
for human use). They found that when doses more compat-
ible with human use were used, no increased osteosarcoma 
risk was seen.26
Since the launch of the medication in December 2002, 
Eli Lilly has maintained a safety monitoring program and 
has identified one possible case of osteosarcoma in a patient 
treated with Forteo®. This was a postmenopausal woman in 
her seventies with a complex medical history who, into her 
second year of therapy, was found to have metastatic cancer. 
She subsequently died, and no autopsy was performed. The 
primary cancer site was never identified; however, the clinical 
suspicion was lung cancer with metastases. The pathol-
ogy consultant felt that the differential diagnosis included 
several tumor types, including an osteosarcoma variant. In 
2006, Eli Lilly submitted the biopsy materials to another 
bone pathology expert who concluded the lesion was an 
osteosarcoma.27
As of 2006, 250,000 patients in the US and 300,000 
patients worldwide were being treated with Forteo®. Given 
that the background incidence of osteosarcoma in the general 
population of 60-year-old men and women is 1:250,000 per 
year, it is difficult to assume causality between Forteo® and 
osteosarcoma.28 Between 2002 and 2009, there have been 
1 million scripts for Forteo®; therefore, just simply based 
on population prevalence alone, there would have been 4 
expected cases of osteosarcoma to date.29 However, under-
reporting always remains a possibility. Eli Lilly is continuing 
to monitor for osteosarcoma in patients treated with their 
product. As a result, teriparatide use should be avoided in 
patients with an increased baseline risk of osteosarcoma, 
which include those with Paget’s disease, prior radiation 
therapy (external or seed implants), unexplained elevations of 
alkaline phosphatase, or in young adults with open epiphyses. 
Similarly, it should not be used in pregnant women.
A theoretical potential exists for teriparatide to acceler-
ate local tumor extension if non-primary bone tumors are 
unknowingly present in bone, as anabolic therapy increases 
bone turnover. This explains the hesitancy to use teriparatide 
in patients with active or recent non-osteosarcoma cancers 
that have a likelihood to metastasize to bone, such as breast, 
prostate, lung, thyroid, or kidney.29
Side effects
Teriparatide is generally well tolerated. In clinical trials, the 
frequency of at least 1 episode of transient hypercalcemia 
in the 4 to 6 hours after Forteo® administration was 11% of 
women and 6% of men. The number of patients treated with 
hypercalcemia verified on consecutive measurements was 
3% in women and 1% in men. Nausea, dizziness, headache, 
and leg cramps can occur in 7% to 10% of patients; however, 
studies evaluating the 20 µg dose reported rates of nausea 
and headache similar to those who received placebo.9,30,31 
Rarely rhinitis, or arthralgias can occur, but these are usu-
ally not severe enough to require discontinuation. Clinically 
insignificant decreases in serum magnesium and increases 
in serum urate levels are seen in both the 20 µg and 40 µg 
dosing. Antibodies to teriparatide have been noted in about 
3% of women with long-term treatment; however hypersensi-
tivity reactions or decreased efficacy has not been seen. Post 
marketing case reports of acute dyspnea, allergic reactions, 
edema (facial/oral), hypercalcemia 13 mg/dL, injection site 
reactions (bruising, pain, swelling), muscle spasm, and urti-
caria have also been reported. None of these adverse events 
occurred more frequently than those with placebo or other 
comparative medications. Side effects did not vary by patient 
age or those with mild to moderate renal impairment.8
Monitoring
Before initiation
It is recommended to obtain a serum calcium, alkaline 
phosphatase, and serum intact PTH before the initiation 
of therapy with teriparatide, as baseline elevations may 
contraindicate therapy. As with all OP treatment regimens, 
adequate calcium and vitamin D supplementation is essential 
for efficacy of treatment. Ensuring vitamin D sufficiency 
(with measurement of serum 25-OH D) before treatment is 
of utmost importance, due to the widespread prevalence of 
insufficiency (especially north of Atlanta, Georgia), as well 
as the possible secondary hyperparathyroid state that can 
result from low vitamin D levels.
Most postmenopausal women require a daily elemen-
tal calcium intake of 1200 to 1500 mg.1 This is the total 
including dietary intake as well as supplement levels. Daily 
ingestion of foods rich in calcium (ie, dairy, dark green leafy 
vegetables) are encouraged with supplementation to meet the 
remaining requirements. Calcium supplementation should International Journal of Women’s Health 2010:2 42
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be divided into 500 mg doses, as doses beyond this exceed 
the renal threshold for absorption. Calcium carbonate needs 
an acidic pH for absorption whereas citrate formulations do 
not. Thus, women taking concomitant antacids and/or with 
co-morbidities that alter gut ph may benefit preferentially 
from calcium citrate supplements.
Many individuals north of the Atlanta region require vita-
min D3 supplementation of at least 1000 to 2000 IU D3/day 
to achieve a mid-range goal of 25 OH vitamin D of 40 to 
50 ng/mL. One can expect a rise in serum of 1 ng/mL/100 IU/day 
cholecalciferol (D3) and 3 months is needed to establish a new 
steady state.1
During therapy
Though no specific recommendations for blood test monitor-
ing during therapy is recommended in the package insert, 
obtaining calcium, phosphorus, and bone-specific alkaline 
phosphatase levels periodically is recommended.
Serum calcium levels should not be checked any earlier 
than at least 12 hours after the administration of the medi-
cation due to the transient hypercalcemia that can be seen. 
If hypercalcemia develops, then oral calcium intake should 
be reduced by 50%, and if calcium elevation persists then 
all external sources of calcium supplementation should be 
stopped. Discontinuation of teriparatide is rarely necessary 
as a result of induced hypercalcemia.29
Investigators have begun to evaluate the use of bone 
formation and turnover markers to follow therapy with 
multiple bone agents. Increases in bone formation markers 
(particularly P1NP) are seen within 1 month of treatment and 
seem to predict gains in BMD during anabolic therapy. Bone 
resorption markers actually increase as well. It is not yet clear 
at present, though, that such monitoring can predict fracture 
efficacy, and thus its clinical use is not well defined at this 
time.32,33 One might consider measuring serum N-terminal 
P1NP at baseline and following it after 3 months, as this 
change had a correlation coefficient of 0.65 for predicting 
the 18-month lumbar spine BMD response.32
Post-treatment care
Although Lindsay et al showed sustained fracture preven-
tion after anabolic therapy cessation, the exact duration 
of this benefit is uncertain.34 In the months and years after 
treatment with anabolic therapy, a significant amount of the 
bone density gained during treatment appears to be lost if no 
further therapy is implemented. Black et al looked at effect 
on BMD that followed anabolic treatment [rhPTH (1-84)] 
treatment with placebo vs. continued alendronate treatment 
in postmenopausal women. Women who had ever been treated 
with BPS for more than 12 months or for shorter intervals 
in recent periods prior to the study were excluded. Though 
the rhPTH (1-84) treatment was only for 1 year, alendronate 
therapy after rhPTH (1-84) significantly increased BMD 
in comparison to the results for placebo after PTH, a dif-
ference particularly evident for BMD in trabecular bone 
of the spine on QCT measurement (increase of 31% in the 
rhPTH–alendronate group vs 14% in the rhPTH–placebo 
group). During year 2, subjects receiving placebo lost sub-
stantial BMD.35 Therefore, administering alendronate after 
a course of anabolic therapy appears to conserve the bone 
gained during that treatment and adds some density on its own. 
The additional density added is roughly similar in magnitude 
to the short-term effect of BPS given to previously untreated 
patients.36 Though alendronate is the post-treatment antire-
sorptive agent commonly evaluated in clinical trials, some sort 
of antiresorptive should follow the use of teriparatide.
Kaufman et al also showed gradual decline of lumbar 
spine and total hip BMD with discontinuation of teriparatide 
after 30 months in men, although the loss was not complete 
with BMD still remaining higher than baseline. Similarly, 
these declines were abated with the addition of subsequent 
antiresorptive therapy post anabolic treatment with resultant 
further increases in BMP.37
Most have utilized treatment with teriparatide according 
to the package insert, with daily therapy for a maximum 
of 24 months followed by available alternative therapy 
thereafter, preferably, BPS. Cosman et al has been studying 
variations in this usual sequencing for those at highest risk 
of fracture. Her group recognized that the maximal anabolic 
window with anabolic agents is within the first 3 to 6 months 
of therapy based on results of bone marker analysis. They 
also noted that there is a seeming resistance to teriparatide’s 
effectiveness in time beyond this first 6 months of use, with 
bone turnover levels subsequently plateauing between 6 to 
12 months after teriparatide initiation. They then theorized 
that a series of intermittent, shorter treatment durations may 
create multiple anabolic windows that would result in a more 
significant overall treatment response rather than sustained 
therapy for 24 months.38,39 Initial studies to evaluate the effec-
tiveness of such variations of regimens are underway without 
definitive randomized controlled trial results to date.
Areas for future research
While much data has accumulated on teriparatide and its use 
in OP, many questions remain unanswered. It remains unclear 
what the optimal duration and sequence of anabolic therapy is, International Journal of Women’s Health 2010:2 43
Teriparatide for postmenopausal osteoporosis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
whether pulsed and repeated vs continuous therapy is superior, 
whether certain combinations of therapy are preferred and/or 
to be avoided, and which PTH formulation may be superior, as 
other formulations of PTH analogues exist and are in develop-
ment (PTH 1-81 Preotact® approved in the EU). Additionally, 
which subsets of patients may best benefit from its use and 
when also remain in question. Finally, hip fracture reduction 
has yet to be proven with teriparatide therapy and requires 
further study, as well as comparative effectiveness trials. 
Newer agents for OP are on the very near horizon within the 
US including strontium ranelate, which has partial anabolic 
and antiresorptive properties. Denosumab, a monoclonal 
antibody rank ligand inhibitor, if approved, will be the first 
biologic therapy for bone health. How to utilize such agents 
in relation to teriparatide is also uncertain.
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